SCHEMBL20138338

SCHEMBL20138338

COC(=O)C1CCN(C(=O)c2cnco2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 1/20 0.52
KDM4E B2RXH2 1/20 0.50
CHRNA4 P43681 2/20 0.49
CHRNB2 P17787 1/20 0.49
CHRNB4 P30926 1/20 0.49
CHRNA3 P32297 1/20 0.49
CHRNA7 P36544 1/20 0.49
TSHR P16473 2/20 0.48
SMN1; SMN2 Q16637 5/20 0.48
NPC1 O15118 4/20 0.46
ALDH1A1 P00352 5/20 0.46
GAA P10253 1/20 0.45
HTT P42858 2/20 0.45
RAB9A P51151 3/20 0.45
USP2 O75604 1/20 0.43
DNMT1 P26358 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18255042 0.86 NPC1 (0.65) KDM4ETSHRSMN1; SMN2NPC1ALDH1A1
SCHEMBL20152893 0.85 RIPK1 (0.55) RIPK1CHRNA4CHRNB2CHRNB4CHRNA3
SCHEMBL18255212 0.83 RIPK1 (0.59) RIPK1KDM4ECHRNA4CHRNB2CHRNB4
SCHEMBL22874982 0.78 CHRNA4 (0.51) RIPK1KDM4ECHRNA4CHRNB2CHRNB4
SCHEMBL20935043 0.77 CHRNA4 (0.48) RIPK1CHRNA4CHRNB2CHRNB4CHRNA3
SCHEMBL28473078 0.76 CHRNA4 (0.52) RIPK1KDM4ECHRNA4CHRNB2CHRNB4
SCHEMBL21584775 0.75 CHRNA4 (0.54) RIPK1CHRNA4CHRNB2CHRNB4CHRNA3
SCHEMBL19004294 0.74 CHRNA4 (0.48) RIPK1CHRNA4CHRNB2CHRNB4CHRNA3
SCHEMBL14731489 0.73 CHRNA4 (0.56) RIPK1CHRNA4CHRNB2CHRNB4CHRNA3
SCHEMBL10724061 0.73 TSHR (0.78) TSHRSMN1; SMN2ALDH1A1GAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230120185-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-04-20 US disclosed
US-11485710-B2 Heterocyclic amides as kinase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2022-11-01 US disclosed
US-20210253532-A1 Heterocyclic Amides as Kinase Inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-08-19 US disclosed
CN-112370452-A Heterocyclic amides as kinase inhibitors 葛兰素史密斯克莱知识产权发展有限公司 2021-02-19 CN disclosed
US-10899716-B2 Heterocyclic amides as kinase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-01-26 US disclosed
EP-3298002-B1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2020-12-16 EP disclosed
CN-107624111-B Heterocyclic amides as kinase inhibitors 葛兰素史密斯克莱知识产权发展有限公司 2020-11-03 CN disclosed
US-20200165205-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-05-28 US disclosed
US-10590085-B2 Heterocyclic amides as kinase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-03-17 US disclosed
US-20180134665-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2018-05-17 US disclosed
CN-107624111-A Heterocyclic amides as kinase inhibitors 葛兰素史密斯克莱知识产权发展有限公司 2018-01-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10590085-B2 Heterocyclic amides as kinase inhibitors MAP3K19, MAP3K20, MAP3K1 RIPK1 414/4885KDM4E 649/4885CHRNA4 4199/4885
US-20210253532-A1 Heterocyclic Amides as Kinase Inhibitors MAP3K19, MAP3K20, MAP3K1 RIPK1 405/4885KDM4E 629/4885CHRNA4 4193/4885
US-20230120185-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS MAP3K19, MAP3K20, MAP3K1 RIPK1 405/4885KDM4E 629/4885CHRNA4 4193/4885
US-11485710-B2 Heterocyclic amides as kinase inhibitors MAP3K19, MAP3K20, MAP3K1 RIPK1 405/4885KDM4E 629/4885CHRNA4 4193/4885
US-10899716-B2 Heterocyclic amides as kinase inhibitors MAP3K19, MAP3K20, MAP3K1 RIPK1 405/4885KDM4E 629/4885CHRNA4 4193/4885
US-20200165205-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS MAP3K19, MAP3K20, MAP3K1 RIPK1 405/4885KDM4E 629/4885CHRNA4 4193/4885
US-20180134665-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS MAP3K19, MAP3K20, MAP3K1 RIPK1 414/4885KDM4E 649/4885CHRNA4 4199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.